Trials / Completed
CompletedNCT00779636
Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)
Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 506 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desloratadine | Desloratadine 10 mg daily x 28 days |
| DRUG | Placebo | Placebo daily x 28 days |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2008-10-24
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00779636. Inclusion in this directory is not an endorsement.